Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Change in Receivables (2020 - 2025)

Cytek Biosciences' Change in Receivables history spans 6 years, with the latest figure at $6.1 million for Q4 2025.

  • For Q4 2025, Change in Receivables fell 34.12% year-over-year to $6.1 million; the TTM value through Dec 2025 reached -$368000.0, down 106.78%, while the annual FY2025 figure was -$368000.0, 106.78% down from the prior year.
  • Change in Receivables reached $6.1 million in Q4 2025 per CTKB's latest filing, up from $587000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $9.3 million in Q4 2024 to a low of -$6.4 million in Q1 2025.
  • Average Change in Receivables over 5 years is $2.2 million, with a median of $2.4 million recorded in 2022.
  • Peak YoY movement for Change in Receivables: crashed 683.33% in 2023, then surged 3647.15% in 2024.
  • A 5-year view of Change in Receivables shows it stood at $720000.0 in 2021, then soared by 1006.11% to $8.0 million in 2022, then tumbled by 103.3% to -$263000.0 in 2023, then soared by 3647.15% to $9.3 million in 2024, then tumbled by 34.12% to $6.1 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Change in Receivables are $6.1 million (Q4 2025), $587000.0 (Q3 2025), and -$652000.0 (Q2 2025).